Hepatitis B vaccine - Celldex Therapeutics

Drug Profile

Hepatitis B vaccine - Celldex Therapeutics

Alternative Names: CDX-2101; HepVax

Latest Information Update: 03 Apr 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lorantis
  • Developer Celldex Therapeutics Inc
  • Class Hepatitis B vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Hepatitis B

Most Recent Events

  • 03 Apr 2009 No development reported - Preclinical for Hepatitis B in Germany (Parenteral)
  • 12 Oct 2005 Lorantis has been acquired by Celldex Therapeutics
  • 25 Jul 2003 Preclinical trials in Hepatitis B treatment in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top